LAUSR

BACKGROUND Pharmaceutical industry exposure is widespread during medical training and may affect education and clinical decision-making. Medical faculties' conflict of interest (COI) policies help to limit this exposure and protect students against commercial influence. AIMS Our aim was to investigate the prevalence, content, and strength of COI policies at Australian medical schools, and changes since a previous assessment conducted in 2009. METHODS We identified policies by searching medical school and host university websites in January 2021, and contacted Deans to identify any missed policies. We applied a modified version of a scorecard developed in previous studies to examine the content of COI policies. All data were coded in duplicate. COI policies were rated on a scale from 0 (no policy) to 2 (strong policy) across 11 items per medical school. Oversight mechanisms and sanctions were also assessed, and current policies compared to the 2009 study. RESULTS Of 154 potentially relevant policies, 152 were university-wide and two were specific to medical schools. No policies covered sales representatives, on-site sponsored education, or free samples. Oversight of consultancies had improved substantially, with 76% of schools requiring pre-approval. Disclosure policies, whilst usually present, were weak, with no public disclosure required. CONCLUSION We found little indication that Australian medical students are protected from commercial influence on medical education, and there has been limited COI policy development within the last decade. More attention is needed to ensure the independence of medical education in Australia. This article is protected by copyright. All rights reserved.